文献速递慢性肾脏病

非透析依赖CKD贫血患者罗沙司他低起始剂量的随机试验

Randomized Trial of Lower-Dose Roxadustat Efficacy and Safety in Non-Dialysis-Dependent CKD-Associated Anemia.
PubMed 文献 · Kidney Int Rep · 2025-01-27

本研究在254例3-5期非透析CKD贫血患者中比较体重基础低起始剂量与标准起始剂量罗沙司他的非劣效性;主要终点(12-16周血红蛋白变化)未达非劣效,但达标比例相当,低剂量波动更小,推荐用于3-4期CKD。

要点

  • 低起始剂量组12-16周血红蛋白增幅未达非劣效于标准剂量。
  • 两组血红蛋白达标(100-120 g/l)比例相当。
  • 低剂量组血红蛋白波动更小,推荐用于3-4期CKD。

核心结论

  • 低起始剂量罗沙司他在血红蛋白达标比例上与标准剂量相当,但主要终点非劣效未成立。
  • 低起始剂量血红蛋白波动更小,推荐用于3-4期CKD患者。

研究设计与样本

  • 随机、1:1、按CKD分期分层的16周试验,共254例3-5期非透析CKD贫血患者。
  • 标准剂量组:<60 kg 70 mg TIW,≥60 kg 100 mg TIW;低剂量组:<60 kg 50 mg TIW,≥60 kg 70 mg TIW。
  • 主要终点为12-16周平均血红蛋白较基线的变化。

主要发现

  • 基线平均血红蛋白89.88(6.90)g/l,4期占39.0%,5期占40.2%。
  • 12-16周血红蛋白增幅:低剂量组21.57 g/l,标准剂量组26.35 g/l,非劣效未成立。
  • 血红蛋白达标(100-120 g/l)比例:低剂量组46.0%,标准剂量组47.2%。
  • CKD 5期亚组血红蛋白增幅低剂量组17.28 g/l vs 标准剂量组26.71 g/l。
  • 低剂量组血红蛋白变化速率较低(2.917 vs 3.376),药物暴露更少,药物相关不良事件率相当。

关键数值与推荐

  • 血红蛋白达标定义为100-120 g/l,低剂量组46.0%,标准剂量组47.2%。
  • CKD 3-4期血红蛋白增幅两组相当,5期低剂量组较低(17.28 vs 26.71 g/l)。

临床怎么用

  • 3-4期非透析CKD贫血可考虑体重基础低起始剂量罗沙司他,以减少血红蛋白波动。
  • 5期非透析CKD患者低起始剂量可能不足,需关注血红蛋白增幅。

局限性

  • 主要终点非劣效未成立,低剂量组血红蛋白增幅较低。
  • 研究样本量254例,亚组分析样本量较小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Different starting doses of roxadustat are used for treating anemia in chronic kidney disease (CKD). We tested the noninferiority of weight-based lower starting dose compared with standard starting dose roxadustat for anemia in stage 3 to 5 CKD without dialysis. METHODS: Patients were randomized (1:1) and stratified by CKD stage to receive weight-based standard (< 60 kg: 70 mg 3 times per week [TIW]; ≥ 60 kg: 100 mg TIW) or 1-step-lower (< 60 kg: 50 mg TIW; ≥ 60 kg: 70 mg TIW) roxadustat starting dose for 16 weeks. The primary endpoint was mean hemoglobin change from baseline over weeks 12 to 16. The secondary endpoints included the proportion achieving hemoglobin 100 to 120 g/l, hemoglobin variability, and rescue therapy. RESULTS: Overall, 254 patients were randomized. The mean (SD) baseline hemoglobin was 89.88 (6.90) g/l. Most patients had stage 4 (39.0%) or stage 5 (40.2%) CKD. Mean hemoglobin increased from baseline at weeks 12 to 16 (lower: 21.57 g/l; standard: 26.35 g/l), but noninferiority was not met. A comparable proportion achieved hemoglobin of 100 to 120 g/l (lower: 46.0%; standard: 47.2%). The hemoglobin increase was comparable in CKD stage 3 to 4, but less with the lower dose in CKD stage 5 (17.28 vs. 26.71 g/l). The lower dose exhibited a lower hemoglobin rate of change (lower: 2.917; standard: 3.376) and less drug exposure. Drug-related adverse event rates were comparable. CONCLUSION: The proportion of patients who achieved the hemoglobin target was comparable between the doses. The lower starting dose had less hemoglobin fluctuation and is recommended for stage 3 to 4 CKD.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Li P, Sun X, Zhang L, et al. Randomized Trial of Lower-Dose Roxadustat Efficacy and Safety in Non-Dialysis-Dependent CKD-Associated Anemia. Kidney Int Rep. 2025. PMID: 40303227. doi:10.1016/j.ekir.2025.01.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。